title: Successful use of the anti-CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis.
abstract: Hemophagocytic lymphohistiocytosis (HLH) is a rare and severe inflammatory disorder marked by abnormal cytotoxic T and natural killer cell activity, resulting in impaired clearance of pathogen, excessive cytokine production, and continued immune system activation. Soluble IL-2 receptor (sIL-2R or sCD25) is typically elevated in HLH and can serve as a marker of disease activity, although its role in the pathophysiology of the disease is unclear. Here we present a case of an adult patient with steroid-dependent HLH who was treated successfully with daclizumab, a monoclonal anti-CD25 antibody, allowing successful withdrawal of steroid therapy without an increase in symptoms.
authors.affiliation: Hematologic Malignancies Program, Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
authors.forename: Rebecca L
authors.initials: RL
authors.lastname: Olin
authors.forename: Kim E
authors.initials: KE
authors.lastname: Nichols
authors.forename: Mojdeh
authors.initials: M
authors.lastname: Naghashpour
authors.forename: Mariusz
authors.initials: M
authors.lastname: Wasik
authors.forename: Brenda
authors.initials: B
authors.lastname: Shelly
authors.forename: Edward A
authors.initials: EA
authors.lastname: Stadtmauer
authors.forename: Dan T
authors.initials: DT
authors.lastname: Vogl
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D015415:Biomarkers; D003520:Cyclophosphamide / Q000008:administration & dosage; D016572:Cyclosporine / Q000627:therapeutic use; D000077561:Daclizumab; D004317:Doxorubicin / Q000008:administration & dosage; D005293:Ferritins / Q000097:blood; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D053645:Interleukin-2 Receptor alpha Subunit / Q000037:antagonists & inhibitors* / Q000276:immunology; D007694:Killer Cells, Natural / Q000276:immunology; D051359:Lymphohistiocytosis, Hemophagocytic / Q000150:complications / Q000188:drug therapy*; D017728:Lymphoma, Large-Cell, Anaplastic / Q000150:complications / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D012008:Recurrence; D016176:T-Lymphocyte Subsets / Q000737:chemistry / Q000276:immunology; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015415:Biomarkers; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D053645:Interleukin-2 Receptor alpha Subunit; D014750:Vincristine; D004317:Doxorubicin; D016572:Cyclosporine; D003520:Cyclophosphamide; D005293:Ferritins; D000077561:Daclizumab; D011241:Prednisone